Oncologist counseling practice and COVID-19 vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity

Autor:	Sara Zarnegar‐Lumley, Cosby A. Stone, Christine M. Smith, Laura L. Hall, Kate E. Luck, Grace Koo, Jessica H. Plager, Elizabeth J. Phillips, Debra L. Friedman
Rok vydání:	2022
Předmět:	Counseling Oncologists COVID-19 Vaccines SARS-CoV-2 Vaccination COVID-19 Hematology Polyethylene Glycols Drug Hypersensitivity Oncology Pediatrics Perinatology and Child Health Asparaginase Humans RNA Messenger
Zdroj:	Pediatric bloodcancer. 69(7)
ISSN:	1545-5017
Popis:	Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID-19) and is important for oncology patients. mRNA-based COVID-19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG-ASNase) and those with PEG-ASNase-associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID-19 vaccines. We, therefore, surveyed oncologists on COVID-19 vaccine counseling practice and vaccination outcomes in COVID-19 vaccination-eligible patients and show safe receipt of mRNA vaccines despite PEG-ASNase hypersensitivity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a250a289422055d399b3520115d9bf7 https://pubmed.ncbi.nlm.nih.gov/35353440 Zobrazit plný text záznamu Plný text